文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胃食管反流病:综述。

Gastroesophageal Reflux Disease: A Review.

机构信息

Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.

Centre for Clinical Research Sormland, Uppsala University, Eskilstuna, Sweden.

出版信息

JAMA. 2020 Dec 22;324(24):2536-2547. doi: 10.1001/jama.2020.21360.


DOI:10.1001/jama.2020.21360
PMID:33351048
Abstract

IMPORTANCE: Gastroesophageal reflux disease (GERD) is defined by recurrent and troublesome heartburn and regurgitation or GERD-specific complications and affects approximately 20% of the adult population in high-income countries. OBSERVATIONS: GERD can influence patients' health-related quality of life and is associated with an increased risk of esophagitis, esophageal strictures, Barrett esophagus, and esophageal adenocarcinoma. Obesity, tobacco smoking, and genetic predisposition increase the risk of developing GERD. Typical GERD symptoms are often sufficient to determine the diagnosis, but less common symptoms and signs, such as dysphagia and chronic cough, may occur. Patients with typical GERD symptoms can be medicated empirically with a proton pump inhibitor (PPI). Among patients who do not respond to such treatment or if the diagnosis is unclear, endoscopy, esophageal manometry, and esophageal pH monitoring are recommended. Patients with GERD symptoms combined with warning symptoms of malignancy (eg, dysphagia, weight loss, bleeding) and those with other main risk factors for esophageal adenocarcinoma, such as older age, male sex, and obesity, should undergo endoscopy. Lifestyle changes, medication, and surgery are the main treatment options for GERD. Weight loss and smoking cessation are often useful. Medication with a PPI is the most common treatment, and after initial full-dose therapy, which usually is omeprazole 20 mg once daily, the aim is to use the lowest effective dose. Observational studies have suggested several adverse effects after long-term PPI, but these findings need to be confirmed before influencing clinical decision making. Surgery with laparoscopic fundoplication is an invasive treatment alternative in select patients after thorough and objective assessments, particularly if they are young and healthy. Endoscopic and less invasive surgical techniques are emerging, which may reduce the use of long-term PPI and fundoplication, but the long-term safety and efficacy remain to be scientifically established. CONCLUSIONS AND RELEVANCE: The clinical management of GERD influences the lives of many individuals and is responsible for substantial consumption of health care and societal resources. Treatments include lifestyle modification, PPI medication, and laparoscopic fundoplication. New endoscopic and less invasive surgical procedures are evolving. PPI use remains the dominant treatment, but long-term therapy requires follow-up and reevaluation for potential adverse effects.

摘要

重要性:胃食管反流病(GERD)定义为反复出现的、令人困扰的烧心和反流,或 GERD 特异性并发症,影响约 20%的高收入国家的成年人口。

观察结果:GERD 可影响患者的健康相关生活质量,并与食管炎、食管狭窄、巴雷特食管和食管腺癌的风险增加相关。肥胖、吸烟和遗传易感性增加 GERD 的发病风险。典型的 GERD 症状通常足以确定诊断,但不太常见的症状和体征,如吞咽困难和慢性咳嗽,可能发生。有典型 GERD 症状的患者可以用质子泵抑制剂(PPI)进行经验性治疗。对于那些对这种治疗没有反应或诊断不明确的患者,建议进行内镜检查、食管测压和食管 pH 监测。有 GERD 症状并伴有恶性肿瘤的警告症状(如吞咽困难、体重减轻、出血)的患者,以及有其他食管腺癌主要危险因素(如年龄较大、男性和肥胖)的患者,应进行内镜检查。生活方式改变、药物治疗和手术是 GERD 的主要治疗选择。减肥和戒烟通常是有用的。用 PPI 进行药物治疗是最常见的治疗方法,在初始全剂量治疗后(通常为奥美拉唑 20mg 每日 1 次),目标是使用最低有效剂量。观察性研究表明,长期使用 PPI 后会出现几种不良反应,但这些发现需要在影响临床决策之前得到证实。在经过彻底和客观的评估后,腹腔镜胃底折叠术是一种有选择的侵袭性治疗方法,特别是对于年轻和健康的患者。内镜和较不侵袭性的手术技术正在出现,这可能会减少长期使用 PPI 和胃底折叠术,但长期的安全性和疗效仍有待科学确立。

结论和相关性:GERD 的临床管理影响着许多人的生活,并导致大量的医疗保健和社会资源消耗。治疗包括生活方式改变、PPI 药物治疗和腹腔镜胃底折叠术。新的内镜和较不侵袭性的手术程序正在不断发展。PPI 的使用仍然是主要的治疗方法,但长期治疗需要随访和重新评估潜在的不良反应。

相似文献

[1]
Gastroesophageal Reflux Disease: A Review.

JAMA. 2020-12-22

[2]
AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.

Clin Gastroenterol Hepatol. 2022-5

[3]
Gastroesophageal Reflux Disease.

Prim Care. 2017-12

[4]
ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?

Arq Gastroenterol. 2018-11

[5]
Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.

Dis Esophagus. 2017-2-1

[6]
Updates on Surgical Treatment for Gastroesophageal Reflux Disease.

Am Surg. 2023-6

[7]
Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.

Surgery. 2013-10

[8]
An Evidence-Based Approach to the Treatment of Gastroesophageal Reflux Disease.

JAMA Surg. 2016-1

[9]
Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.

Dis Esophagus. 2012-8-2

[10]
Laparoscopic fundoplication for gastroesophageal reflux disease.

World J Gastroenterol. 2014-10-21

引用本文的文献

[1]
Sex-specific association of visceral and abdominal subcutaneous adipose tissue with gastroesophageal reflux disease: a large-scale perspective cohort study.

BMC Gastroenterol. 2025-9-2

[2]
Air pollution increases gastroesophageal reflux disease risk: evidence from a prospective cohort study.

Front Public Health. 2025-8-6

[3]
PPI in preventing gastrointestinal injury in minor ischemic stroke or TIA patients at low risk of gastrointestinal bleeding treated with short-term dual antiplatelet therapy.

Front Pharmacol. 2025-7-30

[4]
Association between gastroesophageal reflux disease and DMFT index in the PERSIAN Guilan Cohort Study.

Sci Rep. 2025-8-7

[5]
Health risk factors in different educational groups and their association to Barrett's esophagus.

Wien Klin Wochenschr. 2025-7-25

[6]
Causal relationship between gastroesophageal reflux disease and IgA nephropathy: a Mendelian randomization analysis.

Ren Fail. 2025-12

[7]
Potential Kidney Risks Associated With Clinical Doses of Omeprazole: In Vivo and In Vitro Studies.

Clin Exp Pharmacol Physiol. 2025-8

[8]
Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial.

Sci Rep. 2025-7-2

[9]
Reflux Recurrence After Laparoscopic Fundoplication for Nonerosive Gastroesophageal Reflux Disease.

JAMA Netw Open. 2025-6-2

[10]
Moderate Wine Consumption and Gastrointestinal Diseases.

Nutrients. 2025-5-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索